Press Enter to search · ESC to close

US Stocks

Eli Lilly’s Taltz Plus Zepbound Meets Primary Endpoint in 36-Week Trial

Eli Lilly said the combination of Taltz and Zepbound met the primary endpoint in a 36-week clinical trial. The trial evaluated the two drugs together over the 36-week period. No further efficacy or safety data from the study were disclosed in the announcement.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback